BioMarin Pharmaceuticals BMRN Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's change in other liabilities?
- BioMarin Pharmaceuticals (BMRN) reported change in other liabilities of $8.7M in Q1 2026.
- How has BioMarin Pharmaceuticals's change in other liabilities changed year-over-year?
- BioMarin Pharmaceuticals's change in other liabilities increased by 320.7% year-over-year, from $2.07M to $8.7M.
- What is the long-term trend for BioMarin Pharmaceuticals's change in other liabilities?
- Over 2 years (2022 to 2024), BioMarin Pharmaceuticals's change in other liabilities has grown at a 45.9% compound annual growth rate (CAGR), from $6.93M to $14.76M.
- What does change in other liabilities mean?
- The change in miscellaneous company obligations.
- How do you interpret change in other liabilities?
- Increases represent a source of cash, while decreases represent a use of cash; trends often reflect changes in long-term operational accruals.
- How does change in other liabilities compare across companies?
- Highly dependent on company-specific accounting practices and benefit structures.